Go offline with the Player FM app!
Biosimilars in Action
Manage episode 509496643 series 3342171
Listen in as we discuss considerations, challenges, and strategies related to the use and switching of biosimilars in clinical practice. You’ll hear communication tips to address patient and prescriber concerns as well as operational considerations for integrating biosimilars into practice.
Special guests:
- Bharati Bhardwaja, PharmD, BCPS, LSSBB
- Rheumatology Clinical Pharmacy Specialist
- Kaiser Permanente Colorado
- Megan May, PharmD, BCOP, FHOPA, FAPO
- Clinical Oncology Pharmacy Specialist
- Baptist Health Lexington/Hamburg Cancer Care Center
You’ll also hear practical advice from TRC’s Editorial Advisory Board member:
- Craig D. Williams, PharmD, FNLA, BCPS
- Clinical Professor of Pharmacy Practice
- Oregon Health and Science University
For the purposes of disclosure, Dr. Megan May reports relevant financial relationships [lung cancer] with Amgen, AstraZeneca, Pharmacosmos (speakers bureau). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
This podcast is an excerpt from one of TRC’s monthly live CE webinars, the full webinar originally aired in August 2025.
TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter, Pharmacy Technician’s Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:
- FAQ: Facts About Biosimilars
- Chart: Comparison of Insulins (United States)
- Chart: Biologics for Rheumatoid Arthritis
- Chart: Biologics for Crohn’s Disease
Use code mt1025 at checkout for 10% off a new subscription.
****
📝 We’d love to hear from you!
Take our quick listener survey—it only takes a minute and helps us make the show even better. Plus, you’ll be entered to win a $25 gift card!
📣 Share your thoughts here: https://forms.office.com/r/z3EqDypiJt 📣
****
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.
Chapters
1. Introduction (00:00:00)
2. CE Information (00:02:27)
3. Factors to consider with biosimilars (00:03:15)
4. Who should avoid a biosimilar? (00:06:43)
5. Handling prior adverse reactions (00:08:07)
6. Switching meds (00:08:51)
7. Patient communication & education tactics (00:11:22)
8. Coordinated messaging across the care team (00:15:16)
9. Discussing “generic” vs “biosimilar” (00:16:48)
10. Bringing hesitant prescribers on board (00:18:27)
11. Streamlining biosimilar use (00:22:46)
12. Pharmacy considerations (00:26:51)
13. Conclusion (00:31:04)
46 episodes
Manage episode 509496643 series 3342171
Listen in as we discuss considerations, challenges, and strategies related to the use and switching of biosimilars in clinical practice. You’ll hear communication tips to address patient and prescriber concerns as well as operational considerations for integrating biosimilars into practice.
Special guests:
- Bharati Bhardwaja, PharmD, BCPS, LSSBB
- Rheumatology Clinical Pharmacy Specialist
- Kaiser Permanente Colorado
- Megan May, PharmD, BCOP, FHOPA, FAPO
- Clinical Oncology Pharmacy Specialist
- Baptist Health Lexington/Hamburg Cancer Care Center
You’ll also hear practical advice from TRC’s Editorial Advisory Board member:
- Craig D. Williams, PharmD, FNLA, BCPS
- Clinical Professor of Pharmacy Practice
- Oregon Health and Science University
For the purposes of disclosure, Dr. Megan May reports relevant financial relationships [lung cancer] with Amgen, AstraZeneca, Pharmacosmos (speakers bureau). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
This podcast is an excerpt from one of TRC’s monthly live CE webinars, the full webinar originally aired in August 2025.
TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter, Pharmacy Technician’s Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:
- FAQ: Facts About Biosimilars
- Chart: Comparison of Insulins (United States)
- Chart: Biologics for Rheumatoid Arthritis
- Chart: Biologics for Crohn’s Disease
Use code mt1025 at checkout for 10% off a new subscription.
****
📝 We’d love to hear from you!
Take our quick listener survey—it only takes a minute and helps us make the show even better. Plus, you’ll be entered to win a $25 gift card!
📣 Share your thoughts here: https://forms.office.com/r/z3EqDypiJt 📣
****
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.
Chapters
1. Introduction (00:00:00)
2. CE Information (00:02:27)
3. Factors to consider with biosimilars (00:03:15)
4. Who should avoid a biosimilar? (00:06:43)
5. Handling prior adverse reactions (00:08:07)
6. Switching meds (00:08:51)
7. Patient communication & education tactics (00:11:22)
8. Coordinated messaging across the care team (00:15:16)
9. Discussing “generic” vs “biosimilar” (00:16:48)
10. Bringing hesitant prescribers on board (00:18:27)
11. Streamlining biosimilar use (00:22:46)
12. Pharmacy considerations (00:26:51)
13. Conclusion (00:31:04)
46 episodes
همه قسمت ها
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.